Blog
Background Investigation Methods, Corporate Intelligence & Due Diligence, e-Discovery Techniques, Investigation & Intelligence Feeds, Judgment Enforcement, Legal Enforcement Cases, Legal Ethics & Intelligence, Legal Technology & Intelligence, Witness Credibility Analysis
FDA Approves BMS’s BREYANZI as First MZL CAR T Therapy
On December 4, 2025, the FDA approved a new indication for Bristol Myer Squibb’s BREYANZI (lisocabtagene maraleucel) for the treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of therapy….
By: Goodwin